
SHINE submits drug master file to FDA
SHINE Technologies has submitted its drug master file to the FDA for a material used in precision cancer treatment. The Janesville-based company yesterday announced the submission for non-carrier added lutetium-177 chloride, or Lu-177. This radiopharmaceutical is used alongside a cancer-seeking


















